ArticleHealth science reports2026
Assessing the Impact of Rotavirus Vaccination in Iranian Children Under Five: An Agent-Based Modelling Approach.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Rotavirus is a leading cause of severe diarrhoeal disease in young children worldwide. In 2024, Iran introduced the pentavalent oral vaccine Rotasiil® into its national immunization program. This study aimed to estimate its potential epidemiological impact using an agent-based modeling (ABM) approach. Methods: An ABM was developed in NetLogo 6.4.0 to simulate rotavirus transmission among children under five in urban and rural settings. Agents represented individual children with attributes such as age, mobility, and susceptibility. Transmission occurred through contact within defined spatial grids, with higher probabilities assigned to rural settings to reflect poorer sanitation. Disease progression included incubation, symptomatic period, temporary immunity, and rare mortality. Two vaccination conditions (vaccinated vs. unvaccinated) were simulated, assuming 98% coverage and 55% seroconversion, consistent with Rotasiil-Liquid trial data. Population turnover and births were incorporated. Each condition was run 1,000 times over one simulated year, and incidence rates and symptomatic days per child-year were calculated. Sensitivity analyses tested low- and high-incidence assumptions. Results: In urban settings, vaccination reduced incidence from 0.663 to 0.440 cases per child-year (- 33.6%) and disease days from 3.895 to 2.584 (- 33.7%; Conclusion: Rotasiil is expected to substantially reduce rotavirus burden in Iran, lowering incidence, symptomatic days, and epidemic peak size. These results support the inclusion of rotavirus vaccination as a key child health intervention, though continued post-introduction surveillance remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.